BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 748K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

17 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Recent Progress in Histone Demethylase Inhibitors.EBI
University of Oxford
Inhibition of Histone Demethylases Offers a Novel and Promising Approach for the Treatment of Cancer and Other Diseases.EBI
Therachem Research Medilab (India)
Identification of the KDM2/7 histone lysine demethylase subfamily inhibitor and its antiproliferative activity.EBI
Kyoto Prefectural University of Medicine
Inhibitor scaffold for the histone lysine demethylase KDM4C (JMJD2C).EBI
University of Copenhagen
A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response.EBI
GlaxoSmithKline R&D
Inhibition of demethylases by GSK-J1/J4.EBI
EpiTherapeutics Aps
Combination Therapy and Dual-Target Inhibitors Based on LSD1: New Emerging Tools in Cancer Therapy.EBI
Zhengzhou University
Design, synthesis and biological evaluation of pyrimidine base hydroxamic acid derivatives as dual JMJD3 and HDAC inhibitors.EBI
Tsinghua University
Pharmacological inhibition of KDM5A for cancer treatment.EBI
Ningbo University
Structure-Based Design of Selective Fat Mass and Obesity Associated Protein (FTO) Inhibitors.EBI
University of Oxford
Drug discovery of histone lysine demethylases (KDMs) inhibitors (progress from 2018 to present).EBI
Hangzhou Normal University
Discovery of a potent and selective inhibitor of histone lysine demethylase KDM4D.EBI
Nankai University
Identification of the 2-Benzoxazol-2-yl-phenol Scaffold as New Hit for JMJD3 Inhibition.EBI
Institute of Biomolecular Chemistry (Icb)
Structure-Based Engineering of Irreversible Inhibitors against Histone Lysine Demethylase KDM5A.EBI
The University of Texas M.D. Anderson Cancer Center
From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors.EBI
Genentech